Category Archives: Topics

Fiasp Pediatric Indication Filed in US and EU

Novo Nordisk announced it has submitted EMA and FDA applications for the use of Fiasp in adolescents and pediatrics based on results from the Onset 7 study (children down to age 1). According to the press release, Novo anticipates a response from EMA later in 2019 and an FDA decision in “early 2020.” Below, FENIX provides insight into the Fiasp pediatric filings as well as context from Lilly’s upcoming URLi pediatric study (Pronto-Peds).

This content is for Read Less members only.
Already a member? Log in here

Sota/Dapa T1DM EU Regulatory Analysis; Sota Receives Positive CHMP Opinion

CHMP has adopted a positive opinion for the use of 200 and 400mg Zynquista (sotagliflozin) in T1DM.  Recall, on January 31, CHMP adopted a positive opinion for the use of Forxiga in T1DM (previous FENIX insight). Of note, the proposed limitations for use of both Zynquista and Forxiga are identical. Below, FENIX provides insights from the Zynquista positive CHMP opinion and potential read-through to the upcoming Zynquista FDA action date.

This content is for Read Less members only.
Already a member? Log in here

Xultophy Label Update at Parity with Soliqua

According to Drugs@FDA, Xultophy label was updated to expand the indication for use in patients uncontrolled on OADs. Additionally, the new label also included 3 other major changes: 1) recommended starting dose, 2)  clinical data from DUAL I, DUAL IV trials and 3) a caution for audible clicks. Of note, Novo did not issue a press release on this FDA approval. Below, FENIX provides an analysis of the updated Xultophy label and its impact on the injectable market segment.

This content is for Read Less members only.
Already a member? Log in here

Janssen Diabetes VP Moves to Vertex

As of February 2019, Janssen’s VP and Franchise Medical Leader for the metabolism business, Gary Meininger (pictured below), has left Janssen and is now the SVP and Head of Pipeline Development for Vertex Pharmaceuticals. Prior to his ~9 years at Janssen, Meininger spent 8 years at Merck as a director of Merck Research Laboratories. Below, FENIX provides brief thoughts on Meininger’s departure.

This content is for Read Less members only.
Already a member? Log in here

Soliqua Label Update More Competitive vs. Xultophy and Basaglar

Sanofi announced FDA approval of an updated Soliqua label to expand its indication to patients uncontrolled on OADs. Additionally, Soliqua stability has been extended from 14 days to 28 days (vs. 21 days for Novo’s Xultophy). Below, FENIX provides thoughts on how Sanofi will likely leverage the updated Soliqua indiction to position Soliqua as the first injectable as well as increasing Sanofi’s competitive position vs. Xultophy and Basaglar.

This content is for Read Less members only.
Already a member? Log in here

Tandem and Mylan Q4 ’18 Earnings Updates

Tandem Diabetes Care and Mylan both hosted their respective Q4 ’18 earnings calls. Of note, Mylan did not discuss its biosimilar insulin programs (including bs-glargine) or bs-glucagon. Below, FENIX provides highlights and insights from the Tandem earnings call.

This content is for Read Less members only.
Already a member? Log in here

Diabetes Takes a Backseat During Part II Drug Pricing Hearing

Today, the Senate Finance Committee held the second drug pricing hearing of 2019 (Drug Pricing in America: A Prescription for Change, Part II). Part I was held on January 29, 2019. While the Part I drug pricing hearing spent much time discussing insulin pricing, diabetes-specifically was hardly mentioned. When a specific drug was mentioned, it was most often AbbVie’s Humira. Below, FENIX provides diabetes-related highlights and insights from the hearing.

This content is for Read Less members only.
Already a member? Log in here

MannKind Q4 ’18 Earnings Update

MannKind hosted its Q4 ’18 earnings call and provided updates to its Afrezza business including commercial and clinical activities. Below are highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here

Omnipod Horizon Receives Breakthrough Device Designation; Q4 ’18 Earnings Update

Insulet hosted its Q4 ’18 earnings call and provided updates to its Omnipod business including the development of the Omnipod Horizon hybrid closed-loop. Of note, this is believed to be the first time that Insulet disclosed it received Breakthrough Device Designation for Omnipod Horizon. Below are highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here

Farxiga eGFR Cutoff Lowered; Positive Brilinta T2DM Data

AstraZeneca’s Farxiga franchise labels (Farxiga and Xigduo) have been updated to reduce the eGFR cutoff from 60 to 45 mL/min/1.73m2. Additionally, AZ announced positive topline results from the Brilinta Ph3 THEMIS study in patients with established CAD and T2DM. Below, FENIX provides insight into the lower Farxiga eGFR as well as thoughts on AZ’s strengthening CV protection market position.

This content is for Read Less members only.
Already a member? Log in here